Syra Health Corp (SYRA) Form 10-Q — Nov 3, 2026
Syra Health posted a dramatic turnaround in its Q3 2026 10-Q: nine-month revenue rose 32% to $7.2 million and net income swung to $835,831 from a $761,763 loss a year earlier, with gross margin expanding from 35% to 45%. Q3 alone showed revenue up 52% to $2.56 million and net income of $344,610 versus a $225,902 loss, while operating cash flow of $975,023 lifted cash to $2.38 million. Despite the operational improvement, the company still discloses substantial doubt about its ability to continue as a going concern and warns that federal spending pauses are delaying new government contract awards.
Key figures
- Eps
- $0.06
- Revenue
- 7225238
- Net Income
- 835831
- Total Debt
- 179272
- Revenue Yoy
- 32%
- Total Assets
- 4225390
- Cash Position
- 2383413
- Shares Outstanding
- 13850279
- Q3 eps
- $0.02
- Q3 revenue
- 2557295
- Q3 net income
- 344610
- Q3 revenue yoy
- 52%
- Working capital
- 2962208
- Accumulated deficit
- 8884695
- Operating cash flow
- 975023
- Gross margin prior year
- 35%
- Gross margin nine months
- 45%
- Fssa revenue concentration
- 17%
- Humana revenue concentration
- 35%
- Operating income nine months
- 742556
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.